It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
DNA immunization services and technologies have been developed and optimized at ProteoGenix in order to offer a successful alternative for custom monoclonal or polyclonal antibody generation against difficult-to-express targets but also for early DNA vaccine development studies.
| Hybridoma development via genetic immunization | Polyclonal antibody generation by genetic immunization | Immune antibody library via DNA immunization | |
|---|---|---|---|
| Content |
|
|
|
| Strating Material | Antigen sequence | Antigen sequence | Antigen sequence |
| Deliverable | Culture supernatants | Protein A/G purified serum | Phage library |
| Lead Time | 3 to 6 months | 2 to 3 months | 3 to 5 months |
15 years of expertise in monoclonal antibody development: Our experienced team of account managers can guide you to design the most appropriate strategy to develop the most suitable antibodies for you.
Our prices are among the most competitive ones on the market with unrivaled guarantees.
Injections are optimized to allow reaching high titers for any kind of protein.
Everything can be included from gene synthesis to the development of a stable cell line expressing your recombinant antibody.
We can also perform only small steps of the service and consider Go / No Go stops.
Native protein : Antigen shows proper Post Translational Modifications (PTM) that triggers conformational epitopes leading to higher affinity antibodies, crucial for many applications and especially most therapeutic antibody developments.
Save time : No need for antigen production.
Cost less : No need to produce and purify large amounts of antigen.
No contaminant injected : Co purified proteins, protein purification tags, HCP
High antibody titer : Smaller injections and steady presentation to immune system favors high titers and therefore higher affinity antibodies.
Applications : Antibodies will work in a broader range of application as the antigen presents linear epitopes but also conformational epitopes.
No Antigen needed : Antigens are sometimes difficult to express or purify and to find in catalogs because they are toxic, insoluble, unstable or membrane bound. When produced in recombinant way, it can be different from the native form especially depending on the protein expression system used and therefore lead to irrelevant antibodies.
ProteoGenix’ team of account managers is available to study each customer project in order to define the most suitable strategy to develop antibodies meeting customers’ specifications in terms of antibody performances, deliverables, budget and lead time. Our wide range of technologies and solutions allows us to design optimal strategies no matter the constraints we have to face.
For DNA immunization programs more specifically, we possess an unrivaled experience in all steps of the process including codon optimization, gene synthesis, plasmid preparation, animal injection, hybridoma development and antibody purification. This experience allows us to provide integrated antibody production services by genetic immunization delivering antibodies of strong affinity at very affordable prices in a short period of time.
2. Is this methos suited for all types of antigen species?
3. In which cell type is the antigen transfected?
4. Who should prepare the plasmid to inject?
5. Are nuclear antigens and transmembrane antigens good targets?
Generate high affinity therapeutic antibody development
Use DNA immunization for early phases of DNA vaccination (DNA vaccine development)
Buy genetic immunization for polyclonal antibody production by DNA immunization
For immune library generation followed by phage display screening
For antibody discovery
The principle of genetic immunization for antibody production is to inject to animals a plasmid DNA coding for the targeted antigen instead of injecting the target itself. Our proprietary plasmid that also serves as an adjuvant will transfect animal cells and conduct to in situ expression of the antigen, that will therefore be presented to the immune system in a form usually much closer to the native form of that antigen. The animal then responds normally to the protein target it has expressed in vivo. DNA immunization is therefore an outstanding tool to develop polyclonal and monoclonal antibodies against certain types of targets or to study DNA vaccine candidates at early stage. After years of research ProteoGenix has established high performing SOPs to develop high affinity antibodies through genetic immunization services.
